Avidity Biosciences Inc. (RNA)
Avidity Biosciences Statistics
Share Statistics
Avidity Biosciences has 119.31M shares outstanding. The number of shares has increased by 49.66% in one year.
| Shares Outstanding | 119.31M |
| Shares Change (YoY) | 49.66% |
| Shares Change (QoQ) | 1.87% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 111.07M |
| Failed to Deliver (FTD) Shares | 97.52K |
| FTD / Avg. Volume | 7.34% |
Short Selling Information
The latest short interest is 15.39M, so 12.9% of the outstanding shares have been sold short.
| Short Interest | 15.39M |
| Short % of Shares Out | 12.9% |
| Short % of Float | 14.22% |
| Short Ratio (days to cover) | 10.9 |
Valuation Ratios
The PE ratio is -10.07 and the forward PE ratio is -10.01. Avidity Biosciences's PEG ratio is 14.65.
| PE Ratio | -10.07 |
| Forward PE | -10.01 |
| PS Ratio | 297.77 |
| Forward PS | 4.2 |
| PB Ratio | 2.28 |
| P/FCF Ratio | -10.54 |
| PEG Ratio | 14.65 |
Enterprise Valuation
Avidity Biosciences Inc. has an Enterprise Value (EV) of 485.53M.
| EV / Earnings | -1.51 |
| EV / Sales | 44.56 |
| EV / EBITDA | -1.28 |
| EV / EBIT | -1.28 |
| EV / FCF | -1.58 |
Financial Position
The company has a current ratio of 15.73, with a Debt / Equity ratio of 0.
| Current Ratio | 15.73 |
| Quick Ratio | 15.73 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.48 |
| Cash Flow / Debt | -44.24 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.23% and return on capital (ROIC) is 0%.
| Return on Equity (ROE) | -0.23% |
| Return on Assets (ROA) | -0.21% |
| Return on Capital (ROIC) | 0% |
| Revenue Per Employee | 43.07K |
| Profits Per Employee | -1.27M |
| Employee Count | 253 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -322.3M |
| Effective Tax Rate | 1 |
Stock Price Statistics
The stock price has increased by 52.36% in the last 52 weeks. The beta is 1.02, so Avidity Biosciences's price volatility has been higher than the market average.
| Beta | 1.02 |
| 52-Week Price Change | 52.36% |
| 50-Day Moving Average | 31.17 |
| 200-Day Moving Average | 38.62 |
| Relative Strength Index (RSI) | 45.73 |
| Average Volume (20 Days) | 1.33M |
Income Statement
In the last 12 months, Avidity Biosciences had revenue of 10.9M and earned -322.3M in profits. Earnings per share was -2.89.
| Revenue | 10.9M |
| Gross Profit | 10.9M |
| Operating Income | -378.94M |
| Net Income | -322.3M |
| EBITDA | -378.94M |
| EBIT | -378.94M |
| Earnings Per Share (EPS) | -2.89 |
Balance Sheet
The company has 219.87M in cash and 6.8M in debt, giving a net cash position of 213.07M.
| Cash & Cash Equivalents | 219.87M |
| Total Debt | 6.8M |
| Net Cash | 213.07M |
| Retained Earnings | -893.07M |
| Total Assets | 1.64B |
| Working Capital | 1.53B |
Cash Flow
In the last 12 months, operating cash flow was -300.87M and capital expenditures -7.07M, giving a free cash flow of -307.94M.
| Operating Cash Flow | -300.87M |
| Capital Expenditures | -7.07M |
| Free Cash Flow | -307.94M |
| FCF Per Share | -2.76 |
Margins
Gross margin is 100%, with operating and profit margins of -3.48K% and -2.96K%.
| Gross Margin | 100% |
| Operating Margin | -3.48K% |
| Pretax Margin | -2.96K% |
| Profit Margin | -2.96K% |
| EBITDA Margin | -3.48K% |
| EBIT Margin | -3.48K% |
| FCF Margin | -2.83K% |
Dividends & Yields
RNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -9.43% |
| FCF Yield | -8.42% |
Analyst Forecast
The average price target for RNA is $60, which is 95.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $60 |
| Price Target Difference | 95.8% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Scores
| Altman Z-Score | 15.25 |
| Piotroski F-Score | 4 |